Clinical Trial Update: A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the persistence of immune response and safety after revaccination with an adjuvanted RSV vaccine in adults 18 and older who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV vaccine, adjuvanted

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: RECRUITING